Digging into the NGS Information from a Large-Scale South European Population with Metastatic/Unresectable Pancreatic Ductal Adenocarcinoma: A Real-World Genomic Depiction.

HRR KRAS genomic mutation next generation sequencing pancreatic ductal adenocarcinoma

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
19 Dec 2023
Historique:
received: 05 10 2023
revised: 06 12 2023
accepted: 11 12 2023
medline: 11 1 2024
pubmed: 11 1 2024
entrez: 11 1 2024
Statut: epublish

Résumé

Despite ongoing oncological advances, pancreatic ductal adenocarcinoma (PDAC) continues to have an extremely poor prognosis with limited targeted and immunotherapeutic options. Its genomic background has not been fully characterized yet in large-scale populations all over the world. Methods: Replicating a recent study from China, we collected tissue samples from consecutive Greek patients with pathologically-confirmed metastatic/unresectable PDAC and retrospectively investigated their genomic landscape using next generation sequencing (NGS). Findings: From a cohort of 409 patients, NGS analysis was successfully achieved in 400 cases (56.50% males, median age: 61.8 years). Consistent with a previous study,

Identifiants

pubmed: 38201431
pii: cancers16010002
doi: 10.3390/cancers16010002
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Dimitrios C Ziogas (DC)

First Department of Internal Medicine, Laikon General Hospital, School of Medicine, National Kapodistrian University of Athens, 11527 Athens, Greece.

Eirini Papadopoulou (E)

GeneKor Medical S.A., 15344 Gerakas, Greece.

Helen Gogas (H)

First Department of Internal Medicine, Laikon General Hospital, School of Medicine, National Kapodistrian University of Athens, 11527 Athens, Greece.

Stratigoula Sakellariou (S)

First Department of Pathology, School of Medicine, National Kapodistrian University of Athens, 11527 Athens, Greece.

Evangellos Felekouras (E)

First Department of Surgery, Laikon General Hospital, School of Medicine, National Kapodistrian University of Athens, 11527 Athens, Greece.

Charalampos Theocharopoulos (C)

First Department of Internal Medicine, Laikon General Hospital, School of Medicine, National Kapodistrian University of Athens, 11527 Athens, Greece.

Dimitra T Stefanou (DT)

First Department of Internal Medicine, Laikon General Hospital, School of Medicine, National Kapodistrian University of Athens, 11527 Athens, Greece.

Maria Theochari (M)

First Department of Internal Medicine, Laikon General Hospital, School of Medicine, National Kapodistrian University of Athens, 11527 Athens, Greece.

Ioannis Boukovinas (I)

Department of Medical Oncology, Bioclinic Hospital, 54622 Thessaloniki, Greece.

Dimitris Matthaios (D)

Oncology Department, General Hospital of Rhodes, 85133 Rhodes, Greece.

Anna Koumarianou (A)

Hematology Oncology Unit, Fourth Department of Internal Medicine, School of Medicine, National Kapodistrian University of Athens, 11527 Athens, Greece.

Eleni Zairi (E)

Oncology Department, St. Lukes Hospital, 55236 Thessaloniki, Greece.

Michalis Liontos (M)

Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National Kapodistrian University of Athens, 11527 Athens, Greece.

Konstantinos Koutsoukos (K)

Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National Kapodistrian University of Athens, 11527 Athens, Greece.

Vasiliki Metaxa-Mariatou (V)

GeneKor Medical S.A., 15344 Gerakas, Greece.

George Kapetsis (G)

GeneKor Medical S.A., 15344 Gerakas, Greece.

Angeliki Meintani (A)

GeneKor Medical S.A., 15344 Gerakas, Greece.

Georgios N Tsaousis (GN)

GeneKor Medical S.A., 15344 Gerakas, Greece.

George Nasioulas (G)

GeneKor Medical S.A., 15344 Gerakas, Greece.

Classifications MeSH